The Future of Peptide Medicine: What the PCAC Vote Really Means with Dr. Greg Jones
The Better Yoo Project Podcast
Hosted by Lexi Yoo, FNP-BC/CPNP
About Our Guest
Dr. Greg Jones is a licensed Naturopathic Medical Doctor and earned his degree in Naturopathic Medicine with honors from the Southwest College of Naturopathic Medicine (SCNM) in Tempe Arizona. Dr. Jones has received extensive training in regenerative injection therapy, IV nutritional therapy, bio-identical hormone replacement therapy, and peptide therapy.
Show Notes & Resources
Dr. Jones is here to unpack all the major movement around peptide regulation and what it could mean for your practice. We walk through the recent committee vote that recommends several well-known peptides be reconsidered for compounding, and Dr. Jones explains why this moment matters far beyond just a headline. He breaks down what happened when peptides were moved to a restricted category, how that shift fueled growth of the grey market, and why physician oversight and pharmacy quality control are central to patient safety. We also hear his take on BPC-157, KPV, TB-500, and MOTS-c, including where he has seen them used in practice and why certain delivery methods could return if approvals move forward. We also examine what this vote does not do, why the FDA still holds final authority, and how this step could open doors for more formal research in the future.
Topics discussed in this episode include:
Breaking news from the recent Pharmacy Compounding Advisory Committee (PCAC) meeting.
A background on the 2023 FDA decision to move 19 peptides to Category 2.
How that restriction abruptly limited compounding pharmacy access nationwide.
The grey market expansion as patients seek alternative peptide sources.
Why lack of published safety data fueled regulatory concern.
Why the vote recommends reconsideration for pharmacy compounding pathways.
What the recommendation means for 503A bulk substance consideration.
The importance of physician oversight in peptide prescribing decisions.
How quality control testing differs between compounding pharmacies and online suppliers.
Why harm reduction will become central to the regulatory conversation.
The potential return of multiple peptide delivery methods, including topical and oral forms.
Why BPC-157 is such a versatile clinical tool, and the role of MOTS-c in mitochondrial and metabolic support strategies.
Why over-the-counter injectable peptide access remains unrealistic under current law.
Plans for future peptide reviews scheduled in upcoming regulatory sessions.
We are running a flash special for the YDH Training Academy. Buy peptide module, get the Scaling Your Practice with Peptide Therapy for Free! Use code YAYFDA
Dr. Jones on Instagram: https://www.instagram.com/doctorjones_doctorjones
Dr. Jones on YouTube: https://www.youtube.com/@drgregjonesnmd
Follow our Instagram https://www.instagram.com/lexiyoonp or visit us at https://www.yoodirecthealth.com